Hansa says small trial shows its investigational drug could expand use of Sarepta’s Elevidysnews2025-08-04T11:29:29+00:00August 4th, 2025|Endpoints News|
Allogene says lymphodepletion drug caused patient death, changes CAR-T study designnews2025-08-01T12:30:30+00:00August 1st, 2025|Endpoints News|
4DMT’s eye gene therapy cuts need for injections that treat diabetic macular edemanews2025-07-31T20:41:21+00:00July 31st, 2025|Endpoints News|
Is the Sarepta mess what a political FDA looks like?news2025-07-29T13:31:27+00:00July 29th, 2025|Endpoints News|
Endpoints livestream: Is the Sarepta mess what a politicized FDA looks like?news2025-07-29T12:58:05+00:00July 29th, 2025|Endpoints News|
FDA investigates death of boy who got Elevidys, Roche says death unrelated to therapynews2025-07-26T09:32:16+00:00July 26th, 2025|Endpoints News|
CHMP recommends against Elevidys’ approval in Europenews2025-07-25T10:33:38+00:00July 25th, 2025|Endpoints News|
Rocket cuts 30% of staff as it plots path forward for gene therapiesnews2025-07-24T15:24:25+00:00July 24th, 2025|Endpoints News|
Sarepta would have to conduct new studies to get back on market, FDA official saysnews2025-07-24T15:17:46+00:00July 24th, 2025|Endpoints News|
Still in flux, Galapagos hires new execs, adjusts deal with Gilead, and considers selling its cell therapy businessnews2025-07-23T23:47:06+00:00July 23rd, 2025|Endpoints News|
